268 related articles for article (PubMed ID: 10648454)
1. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.
Lochs H; Mayer M; Fleig WE; Mortensen PB; Bauer P; Genser D; Petritsch W; Raithel M; Hoffmann R; Gross V; Plauth M; Staun M; Nesje LB
Gastroenterology; 2000 Feb; 118(2):264-73. PubMed ID: 10648454
[TBL] [Abstract][Full Text] [Related]
2. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease.
Ardizzone S; Maconi G; Sampietro GM; Russo A; Radice E; Colombo E; Imbesi V; Molteni M; Danelli PG; Taschieri AM; Bianchi Porro G
Gastroenterology; 2004 Sep; 127(3):730-40. PubMed ID: 15362028
[TBL] [Abstract][Full Text] [Related]
3. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
Modigliani R; Colombel JF; Dupas JL; Dapoigny M; Costil V; Veyrac M; Duclos B; Soulé JC; Gendre JP; Galmiche JP; Danne O; Cadiot G; Lamouliatte H; Belaïche J; Mary JY
Gastroenterology; 1996 Mar; 110(3):688-93. PubMed ID: 8608877
[TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
Sutherland LR; Martin F; Bailey RJ; Fedorak RN; Poleski M; Dallaire C; Rossman R; Saibil F; Lariviere L
Gastroenterology; 1997 Apr; 112(4):1069-77. PubMed ID: 9097988
[TBL] [Abstract][Full Text] [Related]
5. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Florent C; Cortot A; Quandale P; Sahmound T; Modigliani R; Sarfaty E; Valleur P; Dupas JL; Daurat M; Faucheron JL; Lerebours E; Michot F; Belaiche J; Jacquet N; Soulé JC; Rothman N; Gendre JP; Malafosse M
Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):229-33. PubMed ID: 8724022
[TBL] [Abstract][Full Text] [Related]
6. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.
Hanauer SB; Korelitz BI; Rutgeerts P; Peppercorn MA; Thisted RA; Cohen RD; Present DH
Gastroenterology; 2004 Sep; 127(3):723-9. PubMed ID: 15362027
[TBL] [Abstract][Full Text] [Related]
7. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group.
Brignola C; Cottone M; Pera A; Ardizzone S; Scribano ML; De Franchis R; D'Arienzo A; D'Albasio G; Pennestri D
Gastroenterology; 1995 Feb; 108(2):345-9. PubMed ID: 7835575
[TBL] [Abstract][Full Text] [Related]
8. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease.
McLeod RS; Wolff BG; Steinhart AH; Carryer PW; O'Rourke K; Andrews DF; Blair JE; Cangemi JR; Cohen Z; Cullen JB
Gastroenterology; 1995 Aug; 109(2):404-13. PubMed ID: 7615189
[TBL] [Abstract][Full Text] [Related]
10. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
Gastroenterology; 1993 Feb; 104(2):435-9. PubMed ID: 8425685
[TBL] [Abstract][Full Text] [Related]
11. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn's disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group.
Ewe K; Böttger T; Buhr HJ; Ecker KW; Otto HF
Eur J Gastroenterol Hepatol; 1999 Mar; 11(3):277-82. PubMed ID: 10333200
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.
Savarino E; Bodini G; Dulbecco P; Assandri L; Bruzzone L; Mazza F; Frigo AC; Fazio V; Marabotto E; Savarino V
Am J Gastroenterol; 2013 Nov; 108(11):1731-42. PubMed ID: 24019080
[TBL] [Abstract][Full Text] [Related]
13. Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort.
Orlando A; Mocciaro F; Renna S; Scimeca D; Rispo A; Lia Scribano M; Testa A; Aratari A; Bossa F; Tambasco R; Angelucci E; Onali S; Cappello M; Fries W; D'Incà R; Martinato M; Castiglione F; Papi C; Annese V; Gionchetti P; Rizzello F; Vernia P; Biancone L; Kohn A; Cottone M
J Crohns Colitis; 2014 Oct; 8(10):1217-21. PubMed ID: 24630485
[TBL] [Abstract][Full Text] [Related]
14. Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease.
de Franchis R; Omodei P; Ranzi T; Brignola C; Rocca R; Prada A; Pera A; Vecchi M; Del Piano M; Ferrara A; Belloli C; Piodi L; Framarin L; Astegiano M; Riccioli FA; Meucci G
Aliment Pharmacol Ther; 1997 Oct; 11(5):845-52. PubMed ID: 9354191
[TBL] [Abstract][Full Text] [Related]
15. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
Bonapace CR; Mays DA
Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
[TBL] [Abstract][Full Text] [Related]
16. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials.
Hanauer SB; Strömberg U
Clin Gastroenterol Hepatol; 2004 May; 2(5):379-88. PubMed ID: 15118975
[TBL] [Abstract][Full Text] [Related]
17. [Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders].
Gendre JP; Mary JY; Florent C; Modigliani R; Colombel JF; Soulé JC; Galmiche JP; Lerebours E; Descos L; Viteau JM
Ann Gastroenterol Hepatol (Paris); 1993 Oct; 29(5):251-6. PubMed ID: 8250520
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for postoperative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC).
Caprilli R; Corrao G; Taddei G; Tonelli F; Torchio P; Viscido A
Dis Colon Rectum; 1996 Mar; 39(3):335-41. PubMed ID: 8603558
[TBL] [Abstract][Full Text] [Related]
19. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA
Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
[TBL] [Abstract][Full Text] [Related]
20. Mesalamine for prophylaxis of small bowel Crohn's disease recurrence.
Bauer WM; Brzezinski A; Lashner BA
Curr Gastroenterol Rep; 1999 Oct; 1(5):377-83. PubMed ID: 10980975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
